Novel Sustained-Release Punctal Plug Lowered IOP
A novel sustained-release travoprost punctal (TP; Ocular Therapeutix, Inc.) plug provided a therapeutic benefit in eyes with ocular hypertension or glaucoma for the targeted duration of 60 days, according to data presented by Robert J. Noecker, MD, at the Annual Meeting of the American Academy of Ophthalmology.1
Twenty patients (36 eyes) at two sites in South Africa were treated with a TP plug (1 per eye) in either the superior or inferior punctum and prospectively observed over 60 days. Dr. Noecker reported that the mean reduction in IOP at 60 days was 23.5% or 6.7 mm Hg at 8 am from a baseline average of 28.7 mm Hg. He added that the TP plug was easy to insert and well tolerated by patients.
“This study demonstrates the promise of delivering sustained-release travoprost via a punctal plug system,” Dr. Noecker told Glaucoma Today. “The delivery system was well retained overall, and patients were comfortable. There were no unanticipated, unexpected, or serious adverse events. The travoprost provided therapeutic benefit for the targeted duration of 60 days, which is approaching a clinically acceptable duration of action for chronic glaucoma therapy. This system could provide a potential alternative to topical eye drop therapy for the treatment of glaucoma and ocular hypertension and minimize the role of patients’ adherence to the therapeutic regimen.”
Dr. Noecker is a consultant to Ocular Therapeutix, Inc.
- Noecker RJ, Wasserman P, Carey MJ. Evaluation of a 60-day travoprost punctum plug for IOP reduction. Paper presented at: The American Academy of Ophthalmology Annual Meeting; November 17, 2013; New Orleans, LA.